Novartis cvay736b2201 (H-42655)
Description
Content
A two-part randomized, double-blind, placebo-controlled multicenter dose ranging and confirmatory study to assess the safety and efficacy of vay736 in autoimmune hepatitis patients with incomplete response to or intolerance of standard therapy (amber).
Contact
Phone 1: 713–798–1037
IRB: H-42655
Status:
Active
Created:
